ATH Alterity Therapeutics Ltd
- 0.005
- +0.001+25.00%
Alterity Therapeutics Ltd News
Alterity Therapeutics on Track to Complete Phase Two Trial of Lead Drug Candidate in November
Press Release: Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund
Alterity Therapeutics Receives AU$3.9 Million R&D Tax Refund
Alterity Therapeutics Price Target Maintained With a $4.00/Share by Benchmark
Alterity Therapeutics Raises AU$3.3 Million for Clinical Trials; Shares Fall 20%
Alterity Therapeutics Advances Phase Two Multiple System Atrophy Trial Following Committee Recommendation
Alterity Therapeutics Completes Securities Purchase Plan
Alterity Dispatches Documents Of Planned Share Sale
Alterity Therapeutics Concludes Second Tranche of Placement of AU$3.5 Million; Shares Plunge 20%
Alterity Therapeutics to Raise Up to AU$2 Million Via Share Purchase Plan
Alterity: Andrews to Support Company During Transition>ATHE
Alterity: Hains Follows Resignation of Kathryn Andrews, CFO Since 2014 >ATHE
Alterity: CFO Appointment Effective Jan 31, 2024 >ATHE
Press Release: Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer
Alterity Therapeutics Shares Up Fivefold on New Parkinson's Drug Data
ADRs Close Lower; Alterity Therapeutics Ltd. Declines 30.3%
Alterity Therapeutics ADRs Shares Dive 31% on Raised Capital
Alterity Therapeutics Raises AU$4.8 Million Via Share Placement
Alterity Therapeutics Completes Recruitment for Phase Two Multiple System Atrophy Trial
Alterity Therapeutics Ltd Files For Mixed Shelf Of Up To $50M
Analysis
Price Target
No Data
